[Genetic Counselor]

Families sometimes notice that one generation appears healthy even though several other relatives have dementia.

This raises an important question: Can dementia skip a generation?

The answer depends on the type of genetic condition and its inheritance pattern.

Understanding Autosomal Dominant Inheritance

Autosomal dominant inheritance means that a pathogenic variant in just one copy of a particular gene can cause a genetic condition.

Familial Alzheimer’s disease can be associated with APP, PSEN1 and PSEN2. Familial frontotemporal dementia can be associated with MAPT, GRN and C9orf72.

If an individual carries a heterozygous pathogenic variant in one of these genes, each biological child has a 50% chance of inheriting that variant.

Consider the following family:

Generation I: Grandfather has a pathogenic variant and develops dementia at 55.

Generation II: His daughter inherits the variant but has not developed symptoms at age 40.

Generation III: Her son inherits the same variant.

The family may initially believe that dementia has skipped Generation II because the daughter appears healthy.

However, she may still be at risk of developing symptoms later in life.

The genetic variant has not skipped a generation. The clinical symptoms simply have not appeared yet.

What Is Reduced Penetrance?

Penetrance refers to the proportion of individuals carrying a particular genetic variant who develop the associated clinical condition.

Some variants show reduced or age-dependent penetrance.

This means that:

Some carriers may develop symptoms relatively early.
Others may develop symptoms much later.
Some carriers may never develop the expected clinical condition.

Therefore, an apparently unaffected parent may still carry a pathogenic variant.

What If There Is No Family History?

A person can occasionally develop genetic dementia even when no other family member is known to have the condition.

Possible explanations include:

De novo variant: A new genetic change that is not detected in either biological parent.

Early death: A parent may have died before reaching the usual age of symptom onset.

Misdiagnosis: Previous generations may not have received an accurate diagnosis.

Reduced penetrance: A carrier may never develop recognisable symptoms.

Incomplete family information: Relevant family history may be unavailable.

A negative family history does not automatically exclude a genetic cause.

How Does a Genetic Counsellor Investigate This?

A genetic counsellor usually collects a three-generation family history, including grandparents, parents, siblings, aunts, uncles and children.

The counsellor records the age of symptom onset, diagnosis, current age or age at death and any history of related neurological conditions.

A pedigree can help identify a possible autosomal dominant inheritance pattern and determine whether genetic testing should be considered.

5. Who Should Be Tested First in a Family?

When a family has a history of dementia, one of the most important questions is: Who should undergo genetic testing first?

The general recommendation is to test an affected family member first, whenever possible.

This approach is called proband-first testing or diagnostic testing of the affected individual.

Why Should an Affected Individual Be Tested First?

Imagine a family in which:

The mother developed dementia at 52.
Her sister developed dementia at 55.
Her brother is currently healthy.
Her daughter is 28 and worried about developing dementia.

The daughter wants to know whether she has inherited the condition.

However, testing the daughter directly without first establishing the genetic cause in her affected mother may not provide a clear answer.

Instead, the preferred approach is to perform genetic testing on the mother.

If a disease-causing variant is identified, the daughter can subsequently undergo targeted testing to determine whether she has inherited the same variant.

What Happens If a Pathogenic Variant Is Identified?

Suppose genetic testing identifies a pathogenic variant in the PSEN1 gene in the affected mother.

This establishes a molecular explanation for the familial Alzheimer’s disease.

Because PSEN1-related familial Alzheimer’s disease follows an autosomal dominant inheritance pattern, each biological child of the mother has a 50% chance of inheriting the variant.

The daughter can now choose to undergo predictive genetic testing after appropriate genetic counselling.

Possible outcomes include:

Positive result: The daughter carries the familial pathogenic variant. This indicates an increased likelihood of developing the associated condition, although the exact age of onset may not be predictable.

Negative result: The daughter does not carry the specific familial pathogenic variant. She is not at increased risk from that particular inherited variant.

Uncertain result: If the affected relative’s testing identifies a variant of uncertain significance (VUS), it cannot be used as a definitive predictive test for other relatives.

What If the Affected Individual Is Unavailable?

Sometimes the affected family member may have died, be unavailable for testing or be unable to provide a sample.

In such situations, testing another affected relative may be considered.

If no affected relative is available, testing an unaffected individual may sometimes be discussed based on the family history. However, the limitations of a negative result must be clearly explained.

A negative result in an unaffected person, when no familial pathogenic variant has previously been established, is generally considered an uninformative negative. It does not necessarily exclude a hereditary cause.

What Type of Genetic Testing May Be Considered?

Depending on the clinical presentation and suspected condition, testing may include:

Targeted single-gene testing.

Hereditary dementia gene panel.

C9orf72 repeat expansion testing.

Whole exome sequencing or whole genome sequencing in selected cases.

Importantly, standard sequencing panels may not reliably detect certain repeat expansions, such as the pathogenic hexanucleotide repeat expansion in C9orf72. A suitable specialised testing method may therefore be required.

[Genetic Counselor]

The age at which dementia develops depends on the underlying condition, the specific genetic variant, family history and other biological factors.

Inherited forms of dementia caused by single-gene pathogenic variants often develop earlier than common age-related forms. However, there is no single age at which all genetic dementias begin.

Early-Onset Alzheimer’s Disease

Early-onset Alzheimer’s disease refers to Alzheimer’s disease that develops before 65 years of age.

Rare pathogenic variants in three genes are strongly associated with autosomal dominant familial Alzheimer’s disease:

APP
PSEN1
PSEN2

Individuals carrying certain pathogenic variants in these genes may develop symptoms during their 40s, 50s or early 60s.

For example, imagine a family in which a father developed Alzheimer’s disease at 48, his sister developed it at 51, and their mother developed similar symptoms in her 50s.

This pattern raises suspicion of autosomal dominant familial Alzheimer’s disease.

Each biological child of an individual carrying a confirmed pathogenic variant has a 50% chance of inheriting that variant.

Frontotemporal Dementia

Frontotemporal dementia (FTD) is another important inherited dementia condition.

FTD commonly affects the frontal and temporal regions of the brain. These areas are involved in personality, behaviour, decision-making, language and social functioning.

Symptoms may include:

Personality changes.
Reduced social awareness.
Impulsive behaviour.
Difficulty with language.
Changes in eating habits.
Loss of empathy.

Genetic FTD is commonly associated with three genes:

C9orf72
GRN
MAPT

The age of onset varies considerably, even among individuals carrying variants in the same gene.

Can Two Individuals With the Same Genetic Variant Develop Dementia at Different Ages?

Yes. This is known as intrafamilial variability.

Consider a family in which a father develops dementia at 48, while his daughter, who carries the same pathogenic variant, remains healthy at 45.

This does not necessarily mean that the daughter will never develop the condition.

Some genetic conditions show age-dependent penetrance, meaning that the likelihood of developing symptoms increases with age.

[Genetic Counselor]

Having a mother with Alzheimer’s disease does not mean that you will definitely develop the condition. However, your risk may be higher than that of someone without an affected first-degree relative.

The actual risk depends on several factors, including the mother’s age at diagnosis, the number of affected relatives and whether a disease-causing genetic variant is present.

Late-Onset Alzheimer’s Disease

Late-onset Alzheimer’s disease generally develops after 65 years of age. It is the most common form and usually results from a combination of ageing, genetic susceptibility, environmental influences and lifestyle factors.

For example, imagine a 75-year-old woman diagnosed with Alzheimer’s disease. She has two children who are currently healthy.

Her children do not automatically inherit Alzheimer’s disease. They may have a somewhat increased risk because their mother is affected, but this does not mean that they will develop the condition.

The APOE gene is an important genetic susceptibility factor.

It has three common alleles:

APOE ε2: Generally associated with a lower risk.

APOE ε3: The most common allele.

APOE ε4: Associated with an increased risk of Alzheimer’s disease.

Having one ε4 allele increases susceptibility, while having two copies generally increases the risk further.

Importantly, APOE ε4 is a risk allele, not a disease-causing mutation. It cannot reliably predict whether an individual will develop Alzheimer’s disease or when symptoms will begin.

Early-Onset Familial Alzheimer’s Disease

The situation is different when a parent develops Alzheimer’s disease at a relatively young age, particularly before 65, and several relatives across generations are also affected.

Rare pathogenic variants in APP, PSEN1 and PSEN2 can cause autosomal dominant familial Alzheimer’s disease.

If a parent carries a confirmed pathogenic variant in one of these genes, each biological child has a 50% chance of inheriting that variant.

This is called autosomal dominant inheritance.

When Should You Consider Genetic Counselling?

Genetic counselling is particularly important when:

The affected parent developed symptoms before 65.

Multiple relatives have Alzheimer’s disease or unexplained dementia.

Several generations on the same side of the family are affected.

A known pathogenic variant has been identified in the family.

Ideally, genetic testing should begin with the affected parent. If a pathogenic variant is identified, adult biological relatives can consider targeted predictive testing after appropriate counselling.

[Genetic Counselor]

Yes, dementia can have a genetic component, but not all dementia is inherited.

Dementia is an umbrella term describing a group of symptoms associated with progressive impairment of cognitive functions. Alzheimer’s disease, vascular dementia, dementia with Lewy bodies and frontotemporal dementia (FTD) are some of the major types.

From a genetic perspective, dementia can broadly be classified into monogenic and multifactorial forms.

Monogenic or Single-Gene Dementia

In a small proportion of families, dementia develops due to a pathogenic variant (disease-causing genetic change) in a specific gene.

Early-onset familial Alzheimer’s disease is associated with pathogenic variants in three important genes:

APP: Amyloid precursor protein.

PSEN1: Presenilin 1.

PSEN2: Presenilin 2.

These genes are involved in amyloid-beta processing. Certain pathogenic variants can contribute to abnormal amyloid-beta accumulation in the brain.

Familial Alzheimer’s disease associated with these genes generally follows an autosomal dominant inheritance pattern. An individual carrying a heterozygous disease-causing variant has a 50% chance of passing it to each biological child.

Multifactorial or Polygenic Dementia

Most Alzheimer’s disease cases, particularly those developing after 65 years, are not caused by a single genetic mutation.

Instead, several factors contribute to disease susceptibility, including:

Increasing age.
Family history.
Genetic susceptibility.
Cardiovascular health.
Diabetes and hypertension.
Smoking and physical inactivity.
Environmental and lifestyle influences.

One important susceptibility gene is APOE. Its ε4 allele is associated with an increased risk of Alzheimer’s disease, particularly when two copies are present.

However, carrying APOE ε4 does not mean that a person will definitely develop Alzheimer’s disease.

Can Dementia Develop Without a Family History?

Yes. Many individuals diagnosed with dementia have no known family history.

This is because most dementia cases are not caused by a single inherited genetic mutation. Age, vascular health, environmental influences and other biological factors also contribute.

When should genetic counselling be considered?

Genetic counselling may be particularly useful when dementia develops at a young age, multiple family members are affected or the family history suggests an autosomal dominant inheritance pattern.

A genetic counsellor can assess the family history, construct a three-generation pedigree and discuss whether genetic testing is appropriate.

[Genetic Counselor]

A cherry-red spot is a characteristic finding observed during an examination of the retina, which is the light-sensitive tissue located at the back of the eye.

It appears as a distinct reddish or cherry-coloured area near the centre of the retina, surrounded by a relatively pale or whitish background.

In GM1 gangliosidosis, this finding occurs because GM1 ganglioside accumulates within retinal ganglion cells. These cells become swollen due to the accumulation of stored material, making the surrounding retinal area appear pale or cloudy.

The central region, known as the fovea, contains relatively few ganglion cells and therefore does not accumulate the same amount of stored material. Its underlying reddish appearance remains visible, producing the characteristic cherry-red appearance.

Is a cherry-red spot specific to GM1 gangliosidosis?

No. Although it is an important clinical clue, a cherry-red spot is not specific to GM1 gangliosidosis.

It can also be observed in other metabolic and neurological conditions, including:
– Tay-Sachs disease.
– Sandhoff disease.
– Niemann-Pick disease.
– Other lysosomal storage disorders.
In infantile GM1 gangliosidosis, cherry-red spots are reported in approximately half of affected infants, although their presence varies between individuals and disease presentations.

How is it identified?

An ophthalmologist can identify a cherry-red spot through a dilated fundoscopic examination, which allows direct visualisation of the retina.

Optical coherence tomography (OCT) may also provide additional information about retinal structural changes.

Importantly, the absence of a cherry-red spot does not exclude GM1 gangliosidosis.

Therefore, this eye finding should always be interpreted alongside the child’s clinical presentation, beta-galactosidase enzyme activity and GLB1 genetic testing results.

[Genetic Counselor]

A cherry-red spot is a characteristic finding observed during an examination of the retina, which is the light-sensitive tissue located at the back of the eye.

It appears as a distinct reddish or cherry-coloured area near the centre of the retina, surrounded by a relatively pale or whitish background.

In GM1 gangliosidosis, this finding occurs because GM1 ganglioside accumulates within retinal ganglion cells. These cells become swollen due to the accumulation of stored material, making the surrounding retinal area appear pale or cloudy.

The central region, known as the fovea, contains relatively few ganglion cells and therefore does not accumulate the same amount of stored material. Its underlying reddish appearance remains visible, producing the characteristic cherry-red appearance.

Is a cherry-red spot specific to GM1 gangliosidosis?

No. Although it is an important clinical clue, a cherry-red spot is not specific to GM1 gangliosidosis.

It can also be observed in other metabolic and neurological conditions, including:
– Tay-Sachs disease.
– Sandhoff disease.
– Niemann-Pick disease.
– Other lysosomal storage disorders.
In infantile GM1 gangliosidosis, cherry-red spots are reported in approximately half of affected infants, although their presence varies between individuals and disease presentations.

How is it identified?

An ophthalmologist can identify a cherry-red spot through a dilated fundoscopic examination, which allows direct visualisation of the retina.

Optical coherence tomography (OCT) may also provide additional information about retinal structural changes.

Importantly, the absence of a cherry-red spot does not exclude GM1 gangliosidosis.

Therefore, this eye finding should always be interpreted alongside the child’s clinical presentation, beta-galactosidase enzyme activity and GLB1 genetic testing results.

[Genetic Counselor]

Diagnosis of GM1 gangliosidosis involves a combination of clinical evaluation, biochemical testing and molecular genetic analysis. Since the condition can present with symptoms that overlap with other lysosomal storage disorders, laboratory confirmation is essential.

1. Clinical evaluation

A paediatrician or clinical geneticist evaluates the child’s medical history, developmental milestones, neurological symptoms and physical features.

Important findings that may raise suspicion include:
– Hypotonia and developmental delay.
– Loss of previously acquired developmental skills.
– Hepatosplenomegaly.
– Coarse facial features.
– Skeletal abnormalities.
– Cherry-red spots on retinal examination.

2. Biochemical enzyme analysis

A key diagnostic investigation is measuring beta-galactosidase enzyme activity.

This is generally performed using a blood sample, particularly leukocytes (white blood cells), or other appropriate laboratory specimens.

In individuals with GM1 gangliosidosis, beta-galactosidase activity is significantly reduced or absent compared with the normal reference range.

This biochemical investigation provides important evidence of the underlying metabolic defect.

3. Molecular genetic testing

Genetic testing is performed to identify pathogenic variants in both copies of the GLB1 gene.

Testing may involve:
– Targeted GLB1 gene sequencing.
– Next-generation sequencing (NGS) panels for lysosomal storage disorders.
– Whole-exome sequencing (WES), when the diagnosis is uncertain.
– Deletion and duplication analysis if sequencing does not identify both disease-causing variants.
Identifying the specific variants helps establish the molecular diagnosis, determine the inheritance pattern and facilitate family testing.

4. Additional investigations

Other investigations may include:
– Ophthalmological examination to identify a cherry-red spot.
– Brain MRI to assess neurological involvement.
– Skeletal X-rays to identify characteristic bone abnormalities.
– Liver and spleen assessment.
Combining enzyme analysis with molecular genetic testing provides a reliable approach to confirming GM1 gangliosidosis and distinguishing it from other metabolic disorders.

[Genetic Counselor]

Currently, there is no established cure or widely approved disease-specific treatment for GM1 gangliosidosis as of November 2026. However, ongoing research is investigating several therapeutic approaches that may help address the underlying genetic and biochemical cause of the condition.

GM1 gangliosidosis is a progressive disorder, meaning that symptoms generally worsen over time, particularly in the infantile form. Treatment therefore focuses primarily on supportive and symptom-based management to improve the child’s comfort, overall health and quality of life.

Supportive care may involve several medical specialists, including paediatric neurologists, metabolic specialists, physiotherapists, occupational therapists, nutritionists and respiratory care teams.

Management strategies may include:
– Nutritional support: Feeding assessments, modified feeding techniques and gastrostomy feeding when swallowing difficulties become severe.
– Seizure management: Antiepileptic medications to control seizures.
– Physiotherapy: Exercises and positioning techniques to maintain joint mobility and reduce complications associated with limited movement.
– Respiratory care: Monitoring and managing recurrent respiratory infections, aspiration and breathing difficulties.
– Pain and comfort management: Appropriate medication and supportive interventions to improve comfort.
– Developmental support: Occupational therapy and other interventions to support the child’s functional abilities.
Researchers are exploring gene therapy, substrate reduction therapy and enzyme-related approaches. Gene therapy is particularly promising because it aims to introduce a functional copy of the GLB1 gene, potentially restoring beta-galactosidase activity and reducing the accumulation of GM1 ganglioside.

However, these approaches remain investigational, and their safety and effectiveness need to be established through clinical trials.

Early diagnosis is important because it allows families to access appropriate specialist care, genetic counselling and information about ongoing research opportunities.

[Genetic Counselor]

GM1 gangliosidosis is an inherited metabolic condition caused by pathogenic variants (disease-causing changes) in both copies of the GLB1 gene. This condition follows an autosomal recessive inheritance pattern, meaning that an affected child inherits one altered copy of the gene from each parent.

The GLB1 gene provides instructions for producing an enzyme called beta-galactosidase (β-galactosidase). This enzyme plays an important role in breaking down complex molecules, particularly GM1 ganglioside, which is a type of glycolipid found in cell membranes and is especially abundant in nerve cells.

When both copies of the GLB1 gene contain disease-causing variants, beta-galactosidase activity becomes significantly reduced or absent. As a result, GM1 ganglioside cannot be broken down effectively and gradually accumulates inside lysosomes, which are specialised structures responsible for cellular waste processing.

This accumulation primarily affects neurons in the brain and spinal cord but can also involve other organs, including the liver, spleen and bones.

Progressive accumulation causes cellular dysfunction, neuronal damage and eventually cell death. This explains the progressive neurological deterioration and developmental regression observed in affected children.

How is it inherited within a family?

When both parents are carriers of a pathogenic GLB1 variant, each pregnancy has:
– 25% chance of having an affected child.
– 50% chance of having a child who is an unaffected carrier.
– 25% chance of having a child who is unaffected and not a carrier.
These probabilities remain the same for every pregnancy, regardless of the outcome of previous pregnancies.

Genetic counselling is important to explain recurrence risks and discuss reproductive options, including prenatal diagnosis and preimplantation genetic testing where appropriate.

[Genetic Counselor]

GM1 gangliosidosis is a rare inherited metabolic disorder that affects the nervous system and other organs. In the infantile form (Type I), symptoms usually begin within the first six months of life, although the age of onset and severity can vary between affected children.

One of the earliest signs is hypotonia, commonly described as floppiness or reduced muscle tone. Parents may notice that their baby feels unusually floppy when held, has difficulty controlling their head or takes longer to achieve expected developmental milestones. Other early symptoms include poor feeding, difficulty swallowing, weak muscle control and reduced responsiveness.

Some infants may also show an exaggerated startle response, particularly to sudden sounds or unexpected movements. This may be accompanied by irritability, excessive crying and sleep disturbances.

As the condition progresses, parents and healthcare professionals may observe:
– Developmental delay or regression, including loss of previously acquired skills such as smiling, rolling over or maintaining head control.
– Enlargement of the liver and spleen (hepatosplenomegaly).
– Coarse facial features, including a prominent forehead, flattened nasal bridge and enlarged tongue.
– Skeletal abnormalities, including changes in bone development.
– An enlarged abdomen due to organ enlargement.
– Seizures and progressive neurological deterioration.
Some infants may also develop a cherry-red spot on examination of the retina.

It is important to recognise that not every child will present with all these features. The combination of developmental regression, hypotonia, organ enlargement and characteristic eye findings should raise suspicion of an underlying lysosomal storage disorder, including GM1 gangliosidosis.

Early recognition and appropriate biochemical and molecular testing are essential for confirming the diagnosis and providing suitable supportive care.

[Genetic Counselor]

Genetic mosaicism is generally not inherited from parents. Most cases develop spontaneously after fertilisation because of a genetic change that occurs during early embryonic cell division.

To understand this, it is important to distinguish between inherited genetic changes and post-zygotic genetic changes.

Inherited genetic variants are usually present in the egg or sperm before fertilisation. When these reproductive cells combine, the resulting embryo carries the genetic alteration from the beginning of development.

In contrast, mosaicism usually develops after fertilisation. A genetic change occurs in one of the developing embryonic cells, resulting in a mixture of genetically different cell populations.

For example, if a chromosomal error occurs during an early embryonic cell division, some cells may develop with the normal chromosome number, while others may carry an additional or missing chromosome.

This is why most cases of mosaicism are considered sporadic rather than inherited.

However, there is an important exception.

Gonadal mosaicism, also known as germline mosaicism, occurs when a genetic change is present in some of a person’s reproductive cells (eggs or sperm), but may be absent from most or all of their other body cells.

For example, a parent may have a pathogenic variant in a proportion of their sperm cells but have no symptoms themselves. If one of those sperm cells carries the variant and fertilises an egg, the child may inherit the variant in essentially all their cells.

This means that even when both parents have normal genetic test results from blood samples, there can occasionally be a risk of recurrence in another pregnancy because the genetic alteration may be present in their reproductive cells.

Gonadal mosaicism is particularly important in genetic counselling when:
– A family has more than one child affected by the same apparently de novo genetic condition.
– Both parents have tested negative for the child’s pathogenic variant in blood.
– A genetic condition is known to have a risk of parental germline mosaicism.
It is also possible for an individual to have both somatic and germline mosaicism, meaning the genetic change is present in some body cells and some reproductive cells.

Therefore, although most mosaicism arises spontaneously after conception, transmission to the next generation is possible when reproductive cells carry the genetic alteration.

[Genetic Counselor]

Yes. A blood-based genetic test can sometimes fail to detect mosaicism, particularly when the genetically altered cell population is absent or present at a very low percentage in the blood.

This happens because mosaicism does not necessarily affect every tissue equally.

Remember that the body develops from a fertilised egg through repeated cell divisions. If a genetic change occurs during embryonic development, the affected cells may contribute to certain tissues but not others.

For example, a person may have a chromosomal abnormality in some skin cells but not in the blood cells. In such a situation, a routine blood chromosome analysis may produce a normal result even though mosaicism is present elsewhere in the body.

This is why the choice of tissue is important in genetic testing.

Different sample types may be considered depending on the suspected condition:
– Peripheral blood: Commonly used for chromosome analysis, microarray testing and molecular genetic investigations.
– Buccal swab: Collects cells from the inside of the cheek and may help identify mosaicism not detected in blood.
– Skin biopsy: Can provide fibroblast cells for chromosome or molecular analysis, particularly when tissue-specific mosaicism is suspected.
– Urine epithelial cells: May be useful for investigating certain forms of mosaicism, depending on the suspected genetic condition.
– Affected tissue: In some situations, testing tissue directly involved in the clinical presentation may provide more useful information.
The appropriate sample depends on the suspected genetic alteration and the laboratory technique being used.

Different testing methods also have different abilities to detect mosaicism.

For example:
– Karyotyping: Can identify chromosomal abnormalities in individual cells, but detection depends on the number of cells examined.
– Chromosomal microarray (CMA): Can detect certain chromosomal imbalances and mosaic changes, although sensitivity depends on the platform, tissue and percentage of affected cells.
– FISH: Can examine individual cells for specific chromosomal abnormalities and may help identify low-level mosaicism.
– Next-generation sequencing (NGS): Can identify low-level mosaic variants when the sequencing depth, variant characteristics and bioinformatics pipeline are suitable.
If clinical findings strongly suggest mosaicism despite a normal blood result, a geneticist or genetic counsellor may recommend testing an additional tissue.

However, a cheek swab or skin biopsy is not automatically required for everyone. The decision should be based on the clinical presentation and suspected genetic condition.

The key message: A normal genetic test result from blood does not always completely exclude mosaicism. Sometimes, the genetic alteration may be present in another tissue that was not tested.

[Genetic Counselor]

Not necessarily. A higher percentage of mosaicism does not always indicate a more severe clinical presentation.

When a genetic laboratory reports mosaicism, it usually provides the percentage of cells carrying a particular genetic alteration in the tissue that was tested.

For example, consider two individuals with mosaic Down syndrome:
– Individual A: 20% of the tested blood cells show trisomy 21.
– Individual B: 60% of the tested blood cells show trisomy 21.
At first glance, it may appear that Individual B should have more severe clinical features because a higher proportion of their blood cells carry the additional chromosome.

However, this conclusion cannot be made from the blood result alone.

The reason is that mosaicism can vary significantly between different tissues of the same individual.

For example, one individual may have a relatively low percentage of trisomic cells in their blood but a higher proportion in other tissues, such as the brain or heart. Another individual may show the opposite pattern.

This variation occurs because the genetic alteration may arise during embryonic development, and different cell populations contribute to different tissues and organs.

Several factors influence the clinical severity of mosaic conditions:

1. Tissue distribution: The location of affected cells is important. A genetic alteration affecting cells in a particular organ may have a greater clinical impact than the same percentage of affected cells in another tissue.

2. Timing of the genetic change: An alteration occurring very early in embryonic development may affect a larger number of tissues, whereas a later event may be restricted to specific cell populations.

3. Functional importance of the affected gene or chromosome: Some genetic changes have significant biological effects even when present in a relatively small proportion of cells.

4. Cell selection: Some genetically altered cells may multiply faster or slower than unaffected cells, changing the proportion of affected cells over time.

5. Individual biological differences: Other genetic and environmental factors may influence the clinical presentation.

Therefore, the percentage reported in a laboratory test should not be used as the only predictor of disease severity.

For genetic counselling, the individual’s clinical features, developmental history, affected organs and appropriate investigations are more important than interpreting the mosaic percentage in isolation.

[Genetic Counselor]

Mosaic Down syndrome can sometimes have milder clinical features than full trisomy 21, but this is not always the case.

To understand the difference, we first need to understand how Down syndrome occurs.

Down syndrome is a chromosomal condition caused by the presence of additional genetic material from chromosome 21.

There are different types of Down syndrome:

1. Full trisomy 21

This is the most common form of Down syndrome. Almost all the individual’s cells contain three copies of chromosome 21 instead of the usual two.

2. Mosaic Down syndrome

In this form, the individual has two or more cell populations. Some cells have the typical 46 chromosomes, while others have 47 chromosomes with an additional copy of chromosome 21.

For example:
– Some cells may have 46 chromosomes (46,XX or 46,XY).
– Other cells may have 47 chromosomes (47,XX,+21 or 47,XY,+21).
3. Translocation Down syndrome

This occurs when extra chromosome 21 material becomes attached to another chromosome, usually through a Robertsonian translocation. The individual has extra chromosome 21 genetic material even though the chromosome count may be 46.

In mosaic Down syndrome, the clinical presentation depends on several factors, including the proportion of trisomic cells, their distribution across different tissues and the individual’s overall genetic and developmental background.

Some individuals may have fewer noticeable physical features, relatively typical developmental milestones or fewer associated medical complications.

However, others may experience significant developmental delays, congenital heart defects, learning difficulties or other health concerns similar to individuals with full trisomy 21.

It is important to understand that the percentage of trisomic cells measured in blood does not necessarily represent the percentage in the brain, heart or other organs.

For this reason, it is not appropriate to predict an individual’s developmental outcome or medical needs based only on the percentage of mosaicism reported in a laboratory result.

Children with mosaic Down syndrome should receive appropriate medical follow-up and health screening, just like children with full trisomy 21.

This may include:
– Cardiac evaluation.
– Thyroid function assessment.
– Hearing and vision screening.
– Developmental assessments.
– Monitoring of growth and nutritional status.

[Genetic Counselor]

Genetic mosaicism is a condition in which an individual has two or more populations of cells with different genetic makeups, even though all those cells belong to the same person.

To understand this, imagine that the human body develops from a single fertilised egg, called a zygote. Normally, as this cell divides repeatedly, it produces daughter cells that carry essentially the same genetic information. These cells eventually develop into different tissues and organs, such as the brain, heart, skin and blood.

However, sometimes a genetic change occurs during one of these cell divisions after fertilisation. As a result, the cells that develop from the affected cell may carry the genetic alteration, while cells developing from unaffected cells retain the original genetic makeup.

This creates two or more genetically different cell populations within the same individual. This phenomenon is called genetic mosaicism.

For example, imagine that a genetic change occurs during the third cell division of an embryo. Some of the cells produced from that division may carry the alteration, while others remain genetically unaffected. As the embryo continues developing, both populations multiply and contribute to different tissues.

Mosaicism can involve different types of genetic changes, including:
– Chromosomal abnormalities, such as an additional chromosome in some cells.
– Structural chromosome changes, such as deletions or duplications.
– Single-gene variants affecting only a proportion of cells.
– Changes in chromosome number, including mosaic aneuploidy.
One well-known example is mosaic Down syndrome, where an individual has two cell populations: some cells have 46 chromosomes, while others have 47 chromosomes with an additional copy of chromosome 21.

The proportion and distribution of affected cells can vary considerably between individuals and tissues.

Importantly, mosaicism does not always cause health problems. Some individuals may have noticeable developmental or medical features, while others may have very mild manifestations or remain asymptomatic.

Therefore, genetic mosaicism is essentially about genetic differences between cells within the same individual, rather than differences between individuals.

[Author]

Posts